Role of surgery in management of type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Mount Sinai journal of medicine, New York

• Publication date

  2009-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/msj.20114PMID 19421971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.

  2008cited by this paper
• Effects of Gastric Bypass and Gastric Banding on Glucose Kinetics and Gut Hormone Release

  2008cited by this paper
• Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008 The recommendations in this article are based on the evidence reviewed in the following publication: Standards of care for diabetes (Technical Review). Diabetes Care 17:1514–1522, 1994. Originally approved 1988. Most recent review/revision, October 2007.

  2008cited by this paper
• A Comparison of a Personal Series of Biliopancreatic Diversion and Literature Data on Gastric Bypass Help to Explain the Mechanisms of Resolution of Type 2 Diabetes by the Two Operations

  2008cited by this paper
• Ileal Transposition Controls Diabetes as Well as Modified Duodenal Jejunal Bypass With Better Lipid Lowering in a Nonobese Rat Model of Type II Diabetes by Increasing GLP-1

  2008cited by this paper
• Type 2 Diabetes Mellitus and the Metabolic Syndrome Following Sleeve Gastrectomy in Severely Obese Subjects

  2008cited by this paper
• Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass

  2007cited by this paper
• The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats.

  2007cited by this paper
• Duodenal Switch: Long-Term Results

  2007cited by this paper
• How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number.

  2007cited by this paper
• Effects of bariatric surgery on mortality in Swedish obese subjects.

  2007cited by this paper
• Short-term Effects of Sleeve Gastrectomy on Type 2 Diabetes Mellitus in Severely Obese Subjects

  2007cited by this paper
• EFFICACY OF SURGERY IN THE MANAGEMENT OF OBESITY‐RELATED TYPE 2 DIABETES MELLITUS

  2007cited by this paper
• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects.

  2006cited by this paper
• Prevalence of overweight and obesity in the United States, 1999-2004.

  2006cited by this paper
• Treatment of Mild to Moderate Obesity with Laparoscopic Adjustable Gastric Banding or an Intensive Medical Program

  2006cited by this paper
• The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis.

  2006cited by this paper
• Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity

  2006cited by this paper
• Impact of Recent Increase in Incidence on Future Diabetes Burden

  2006cited by this paper
• Type 2 Diabetes and Weight Loss following Biliopancreatic Diversion for Obesity

  2006cited by this paper
• Differential Effects of Gastric Bypass and Banding on Circulating Gut Hormone and Leptin Levels

  2006cited by this paper
• GLP-1 and Changes in Glucose Tolerance following Gastric Bypass Surgery in Morbidly Obese Subjects

  2006cited by this paper
• The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes

  2006cited by this paper
• Effectiveness of Laparoscopic Sleeve Gastrectomy (First Stage of Biliopancreatic Diversion with Duodenal Switch) on Co-Morbidities in Super-Obese High-Risk Patients

  2006cited by this paper
• Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters

  2006cited by this paper
• Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

  2005cited by this paper
• Loss of Insulin Resistance after Roux-en-Y Gastric Bypass Surgery: a Time Course Study

  2005cited by this paper
• The Mechanisms of Surgical Treatment of Type 2 Diabetes

  2005cited by this paper
• Laparoscopic Adjustable Gastric Banding versus Open Vertical Banded Gastroplasty: A Prospective Randomized Trial

  2005cited by this paper
• Long-Term Outcomes after Gastric Bypass

  2005cited by this paper
• Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats.

  2005cited by this paper
• Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study.

  2005cited by this paper
• Trends in bariatric surgical procedures.

  2005cited by this paper
• Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin.

  2005cited by this paper
• Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study.

  2005cited by this paper
• U.S. experience with 749 laparoscopic adjustable gastric bands: intermediate outcomes

  2005cited by this paper
• Changes in Glucagon-like Peptide-1 (GLP-1) Secretion after Biliopancreatic Diversion or Vertical Banded Gastroplasty in Obese Subjects

  2005cited by this paper
• Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

  2005cited by this paper
• Rapid Resolution of Diabetes after Gastric Bypass

  2005cited by this paper
• Is roux-en-y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients?

  2005cited by this paper
• Changes in Insulin Resistance Following Bariatric Surgery and the Adipoinsular Axis: Role of the Adipocytokines, Leptin, Adiponectin and Resistin

  2005cited by this paper
• Leptin reduces glucose transport and cellular ATP levels in INS-1 beta-cells.

  2004cited by this paper
• Effect of Lap-Band®-Induced Weight Loss on Type 2 Diabetes Mellitus and Hypertension

  2004cited by this paper
• The Enteroinsular Axis and the Recovery from Type 2 Diabetes after Bariatric Surgery

  2004cited by this paper
• Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

  2004cited by this paper
• Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.

  2004cited by this paper
• Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution.

  2004cited by this paper
• Bariatric surgery: a systematic review and meta-analysis.

  2004cited by this paper
• Effect of Duodenal–Jejunal Exclusion in a Non-obese Animal Model of Type 2 Diabetes: A New Perspective for an Old Disease

  2004cited by this paper
• Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization

  2004cited by this paper
• The surgical management of severe obesity.

  2004cited by this paper
• Hormonal Changes after Roux-en Y Gastric Bypass for Morbid Obesity and the Control of Type-II Diabetes Mellitus

  2004cited by this paper
• Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery.

  2003cited by this paper
• Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans.

  2003cited by this paper
• Adiponectin and protection against type 2 diabetes mellitus.

  2003cited by this paper
• Diabetes and Hypertension in Severe Obesity and Effects of Gastric Bypass-Induced Weight Loss

  2003cited by this paper
• Effect of Significant Intermediate-term Weight Loss on Serum Leptin Levels and Body Composition in Severely Obese Subjects

  2003cited by this paper
• Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion.

  2003cited by this paper
• Lap-Band®: Outcomes and Results

  2003cited by this paper
• Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass.

  2003cited by this paper
• Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects.

  2003cited by this paper
• Insulin Resistance, Leptin and TNF-α System in Morbidly Obese Women after Gastric Bypass

  2003cited by this paper
• Ghrelin concentrations in morbidly obese patients after adjustable gastric banding.

  2003cited by this paper
• Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus

  2003cited by this paper
• Lap-band: outcomes and results.

  2003cited by this paper
• Treating Diabetes in the Morbidly Obese by Laparoscopic Gastric Banding

  2003cited by this paper
• Inhibition of food intake in obese subjects by peptide YY3-36.

  2003cited by this paper
• Gut adaptation and the glucagon-like peptides

  2002cited by this paper
• Potential of Surgery for Curing Type 2 Diabetes Mellitus

  2002cited by this paper
• Plasma adiponectin levels in overweight and obese Asians.

  2002cited by this paper
• Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation*

  2002cited by this paper
• Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding.

  2002cited by this paper
• Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study.

  2002cited by this paper
• Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.

  2002cited by this paper
• Malabsorptive gastric bypass in patients with superobesity

  2002cited by this paper
• Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

  2002cited by this paper
• Gut hormone PYY3-36 physiologically inhibits food intake

  2002cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion.

  2002cited by this paper
• Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

  2001cited by this paper
• Enhanced dietary fat clearance in postobese women.

  2001cited by this paper
• Long-or short-limb gastric bypass?

  2001cited by this paper
• Etiology of Type II Diabetes Mellitus: Role of the Foregut

  2001cited by this paper
• The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

  2001cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity

  2000cited by this paper
• Differentiated long-term effects of intentional weight loss on diabetes and hypertension.

  2000cited by this paper
• Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines · Adipocyte‐derived Bioactive Substances

  1999cited by this paper
• Ilial Transposition and Enteroglucagon/GLP-1 in Obesity (and Diabetic?) Surgery

  1999cited by this paper
• Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study.

  1999cited by this paper
• Biliopancreatic Diversion with a Duodenal Switch

  1998cited by this paper
• Response to Intensive Therapy Steps and to Glipizide Dose in Combination With Insulin in Type 2 Diabetes: VA feasibility study on glycemic control and complications (VA CSDM)

  1998cited by this paper
• Biliopancreatic Diversion

  1998cited by this paper
• Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity

  1998cited by this paper
• A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?

  1998cited by this paper
• The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus

  1997cited by this paper
• Leptin Suppression of Insulin Secretion by the Activation of ATP-Sensitive K+ Channels in Pancreatic β-Cells

  1997cited by this paper
• Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity

  1997cited by this paper

• Clinical and economic analysis of bariatric interventions in the treatment of obesity in the Russian Federation

  2023cites this paper
• Evolution of Inflammatory and Oxidative Stress Markers in Romanian Obese Male Patients with Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy: One Year Follow-Up

  2020cites this paper
• Clinical Effectiveness of Routine Pathological Exam after Bariatric Laparoscopic Sleeve Gastrectomy

  2018cites this paper
• Laparoscopic vertical sleeve gastrectomy

  2017cites this paper
• Effects of Bariatric Surgery on Comorbid Conditions Associated with Morbid Obesity

  2015cites this paper
• Identification of factors predictive of outcome following Roux-en-Y gastric bypass for obesity

  2014cites this paper
• Biological effects of bariatric surgery on obesity-related comorbidities.

  2013cites this paper
• Preoperatively determinable factors predictive of diabetes mellitus remission following Roux-en-Y gastric bypass: a review of the literature

  2013cites this paper
• Type 2 diabetes in obese patients with body mass index of 30-35 kg/m2: sleeve gastrectomy versus medical treatment.

  2012cites this paper
• Short-term medication cost savings for treating hypertension and diabetes after gastric bypass.

  2012cites this paper
• [Roux-en-Y gastric bypass for treatment of patients with DM type 2 and BMI of 30 to 35 Kg/m²].

  2012cites this paper
• Bypass gástrico en Y de Roux para el tratamiento de pacientes con diabetes mellitus tipo II con IMC de 30 a 35 kg/m2

  2012cites this paper
• Effects of Sleeve Gastrectomy in Neonatally Streptozotocin-Induced Diabetic Rats

  2011cites this paper
• Surgical therapy for diabesity.

  2010cites this paper
• Metabolic Surgery for the Treatment of Type 2 Diabetes in Patients with BMI <35 kg/m2: An Integrative Review of Early Studies

  2010cites this paper
• Prospective Study of Self-Reported Diabetes and Risk of Upper Gastrointestinal Cancers

  2010cites this paper
• Metabolic management following bariatric surgery.

  2010cites this paper